Cargando…

Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines

Detalles Bibliográficos
Autores principales:	Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520022/ https://www.ncbi.nlm.nih.gov/pubmed/33739363 http://dx.doi.org/10.1093/asj/sjab111

Ejemplares similares

Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2019)

Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial
por: Ascher, Benjamin, et al.
Publicado: (2020)

Response to “Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance”
por: Ascher, Benjamin, et al.
Publicado: (2020)

Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
por: Hilton, Said, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
por: Kestemont, Philippe, et al.
Publicado: (2021)

Repeated Full-Face Aesthetic Combination Treatment With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin-Boosting Hyaluronic Acid After Monotherapy With AbobotulinumtoxinA or Hyaluronic Acid Filler
por: Cartier, Hugues, et al.
Publicado: (2020)

Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study
por: Wu, Yan, et al.
Publicado: (2022)

Effects of repeated abobotulinumtoxinA injections in upper limb spasticity
por: Gracies, Jean‐Michel, et al.
Publicado: (2017)

Correction: Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study
por: Wu, Yan, et al.
Publicado: (2023)

Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy
por: Delgado, Mauricio R., et al.
Publicado: (2017)

A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines
por: Schlessinger, Joel, et al.
Publicado: (2021)

Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension
por: Gracies, Jean-Michel, et al.
Publicado: (2017)

A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines
por: Punga, Anna Rostedt, et al.
Publicado: (2016)

Subject satisfaction and psychological well‐being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines
por: Dayan, Steven, et al.
Publicado: (2022)

The Practical Use of AbobotulinumtoxinA in Aesthetics
por: Kane, Michael A. C., et al.
Publicado: (2017)

New Uses of AbobotulinumtoxinA in Aesthetics
por: Schlessinger, Joel, et al.
Publicado: (2017)

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

AbobotulinumtoxinA in the Management of Hallux Valgus in Adult Patients: Results of a Randomised And Placebo-Controlled Phase 2 Trial
por: Silva, Robert, et al.
Publicado: (2020)

AbobotulinumtoxinA: A 25-Year History
por: Monheit, Gary D., et al.
Publicado: (2017)

Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies
por: Esquenazi, Alberto, et al.
Publicado: (2020)

AbobotulinumtoxinA (Dysport(®)) Improves Function According to Goal Attainment in Children With Dynamic Equinus Due to Cerebral Palsy
por: Tilton, Ann, et al.
Publicado: (2017)

Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat‐treatment study
por: Delgado, Mauricio R, et al.
Publicado: (2020)

Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study
por: Rappl, Thomas, et al.
Publicado: (2013)

Introduction to the Supplement: A Review of AbobotulinumtoxinA (Dysport)
por: Dover, Jeffrey S.
Publicado: (2017)

The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury
por: Esquenazi, Alberto, et al.
Publicado: (2020)

PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022)

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport(®)/Azzalure(®)): Primary Results of the APPEAL Noninterventional Study
por: Gubanova, Elena, et al.
Publicado: (2018)

Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment
por: Wissel, Jörg, et al.
Publicado: (2020)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration
por: Nestor, Mark, et al.
Publicado: (2017)

Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice
por: Trosch, Richard M., et al.
Publicado: (2020)

Conversion to AbobotulinumtoxinA Increases Waning Time and Efficacy for Cervical Dystonia
por: Samotus, Olivia, et al.
Publicado: (2023)

A Cost-Effectiveness and Budget Impact Analysis of AbobotulinumtoxinA in Greece
por: Nomikos, Nikolaos, et al.
Publicado: (2023)

A 12-Month Follow-up, Randomized Comparison of Effectiveness and Safety of Two Hyaluronic Acid Fillers for Treatment of Severe Nasolabial Folds
por: Ascher, Benjamin, et al.
Publicado: (2017)

Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial
por: Esquenazi, Alberto, et al.
Publicado: (2020)

Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm
por: Dashtipour, Khashayar, et al.
Publicado: (2015)

OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review
por: Dashtipour, Khashayar, et al.
Publicado: (2015)

Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity
por: Dashtipour, Khashayar, et al.
Publicado: (2016)

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review
por: Cohen, Joel L., et al.
Publicado: (2017)

Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
por: Muthukumar, Madhusubramanian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jji8ngelrcrdii5up66bn5qptn